June 27th 2025
In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.
June 9th 2025
Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.
April 6th 2025
Oncology nurses can enhance endometrial cancer recovery by fostering strong social support networks and improving communication with the patient.
April 4th 2025
Biocartis announced the launch of its real-time quantitative polymerase chain reaction assay to detect POLE and POLD1 mutations in endometrial cancer.
March 26th 2025
The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by results of a real-world study.
Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS
Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC
No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases
Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break